Vision-Sciences (VSCI) 1.04 $VSCI
Vision-Sciences Announces Record Revenues of $5.0 Million for Fourth Quarter and $17.1 Million for Full Year Fiscal 2014
GlobeNewswire - Mon Apr 28, 3:31PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced financial results for the fourth quarter and full year fiscal 2014, ended March 31, 2014.
Vision-Sciences to Host Fourth Quarter and Full Year Fiscal 2014 Results Call
GlobeNewswire - Mon Apr 21, 11:30AM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the fourth quarter and full year fiscal 2014, ended March 31, 2014, after the market closes on Monday, April 28, 2014. Howard Zauberman, President and Chief Executive Officer, and Keith Darragh, VP, Finance, will host a conference call to discuss the results as follows:
Vision-Sciences to Discuss EndoSheath(R) Technology on "Taking Stock with Pimm Fox"
GlobeNewswire - Mon Mar 17, 3:43PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, is pleased to announce that Cheryl Pegus, M.D., President of Caluent, Director and Strategic Advisor of Glytec, and the Lead Independent Director of Vision-Sciences, will appear on a segment of the Bloomberg News TV show "Taking Stock with Pimm Fox" on Wednesday, March 19, 2014 during the 5:00 - 6:00 PM EDT hour.
Vision-Sciences to Present at BTIG's Inaugural Snowbird Medical Technology and Diagnostics Conference
GlobeNewswire - Thu Mar 13, 12:40PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, announced today that Howard Zauberman, President and Chief Executive Officer, will participate in BTIG's Inaugural Snowbird Medical Technology and Diagnostics Conference on Tuesday, March 18, 2014.
Patient Safety Awareness Week Brings Awareness to Health Care-Acquired Infection
GlobeNewswire - Tue Mar 04, 7:00AM CST
Vision-Sciences' EndoSheath Technology Provides Guaranteed Sterility
Hospitals Face New Superbug Liabilities
GlobeNewswire - Mon Feb 10, 7:02AM CST
Superbugs. Nightmare Bacteria. Antibiotic Resistant Strains. No matter what you call it, it's bad news for hospitals, which face increasingly stringent financial penalties under the Affordable Care Act. Specifically, patient readmissions and follow-up diagnostics due to hospital-acquired infections are increasingly not covered for reimbursement depending on the hospital's track record and other associated factors.
Vision-Sciences Announces Revenue of $4.5 Million for Third Quarter and $12.1 Million for First Nine Months of Fiscal 2014
GlobeNewswire - Mon Feb 03, 3:30PM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced financial results for the third quarter and first nine months of fiscal year 2014, ended December 31, 2013.
4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 31, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
Vision-Sciences to Host Third Quarter Fiscal 2014 Results Call
GlobeNewswire - Fri Jan 24, 8:44AM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the third quarter of fiscal 2014, ended December 31, 2013, after the market closes on Monday, February 3, 2014. Howard Zauberman, President and Chief Executive Officer, and Keith Darragh, VP, Finance, will host a conference call to discuss the results as follows:
4 Stocks Under $10 Moving Higher
at The Street - Wed Jan 15, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Vision-Sciences' EndoSheath(R) Technology Offers Patented Solution to "Nightmare Bacteria"
GlobeNewswire - Mon Jan 13, 7:00AM CST
An outbreak of "Nightmare Bacteria," also known as the "Super Bug," has raised new alarm bells in the healthcare industry over patient safety. The concern stems from 44 newly reported cases of cross-contamination infections as a result of endoscopic procedures done at Advocate Lutheran General Hospital, located just outside of Chicago.*
Vision-Sciences Selected as Preferred Vendor for Endoscopy Equipment by 21st Century Oncology
GlobeNewswire - Thu Dec 19, 7:00AM CST
Orangeburg, NY - December 19, 2013- Vision-Sciences, Inc. (NASDAQ: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, has entered into an agreement with 21 Century Oncology, Inc., under which Vision-Sciences is 21 Century's Preferred Vendor of Choice for endoscopy equipment used for evaluation and treatment procedures in multiple therapeutic and cancer care areas. The equipment agreement includes several of the company's advanced fiberoptic and video based endoscopic imaging products, including flexible laryngoscopes, transnasal esophagoscopes, bronchoscopes, and cystoscopes, all of which are utilized in the diagnosing, treatment, and management of head and neck, esophageal, lung, and bladder cancers.
Vision-Sciences Launches Authorized Repair Center for Europe
GlobeNewswire - Fri Dec 06, 7:00AM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced the full launch of the Company's official and authorized fiber and video endoscope repair center for Europe through an exclusive agreement with Rescope, a Netherlands-based facility dedicated to the technical management and repair of endoscopes.
Vision-Sciences Promotes Howard Zauberman to Chief Executive Officer and President, and Appoints Him to Board of Directors
GlobeNewswire - Tue Nov 26, 7:00AM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that effective today, Howard Zauberman, currently serving as Interim Chief Executive Officer, has been promoted to Chief Executive Officer and President. The Board also elected Mr. Zauberman to the Board of Directors to serve as a Class I director.
Annual ECRI List of Top 10 Health Technology Hazards Underscores Critical Need for Vision-Sciences' EndoSheath(R) Technology
GlobeNewswire - Mon Nov 18, 7:00AM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, announced today that for the fourth consecutive year, the ECRI Institute listed "Inadequate Reprocessing of Endoscopes and Surgical Instruments" among the top ten most dangerous technology hazards.
Vision-Sciences to Host One-on-Ones at Brean Capital 2013 Life Sciences Summit in NYC on November 25th
GlobeNewswire - Fri Nov 15, 12:00PM CST
Vision-Sciences, Inc. (Nasdaq:VSCI) announced today that Howard Zauberman, Interim Chief Executive Officer and Keith Darragh, VP Finance, will host one-on-one meetings at the Brean Capital 2013 Life Sciences Summit on November 25, 2013.
Vision-Sciences Announces Revenue of $4.0 Million for Second Quarter and $7.6 Million for First Half of Fiscal 2014
GlobeNewswire - Mon Nov 11, 3:30PM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced financial results for its second quarter and first half of fiscal year 2014, ended September 30, 2013.
Evaluation at UK Deployed Field Hospital Demonstrates Advantages of Vision-Sciences' EndoSheath(R) Technology for Bronchoscopy
GlobeNewswire - Mon Sep 09, 7:40AM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced positive results from a three-month evaluation completed in 2012 by the British Army at Camp Bastion, a deployed field hospital in Afghanistan. The research evaluated the efficacy and utility of our flexible bronchoscope with EndoSheath technology and its rapid, simplified cleaning routine versus conventional bronchoscopes, which require specialized, complicated disinfection processes between each use.
Vision-Sciences Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon Aug 12, 3:30PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI) today announced financial results for the first quarter of fiscal 2014, ended June 30, 2013. Highlights include:
Vision-Sciences to Discuss First Quarter of Fiscal 2014 Results on August 13 Conference Call
GlobeNewswire - Thu Aug 01, 3:30PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the first quarter of fiscal 2014, ended June 30, 2013, after the market closes on Monday, August 12, 2013. Howard Zauberman, Interim Chief Executive Officer, and John Vittoria, Interim VP Finance, will host a conference call to discuss the results as follows:
Vision-Sciences Announces Record Revenues of $5.0 Million for Fourth Quarter and $17.1 Million for Full Year Fiscal 2014
GlobeNewswire - Mon Apr 28, 3:31PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced financial results for the fourth quarter and full year fiscal 2014, ended March 31, 2014.
Vision-Sciences to Host Fourth Quarter and Full Year Fiscal 2014 Results Call
GlobeNewswire - Mon Apr 21, 11:30AM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the fourth quarter and full year fiscal 2014, ended March 31, 2014, after the market closes on Monday, April 28, 2014. Howard Zauberman, President and Chief Executive Officer, and Keith Darragh, VP, Finance, will host a conference call to discuss the results as follows:
Vision-Sciences to Discuss EndoSheath(R) Technology on "Taking Stock with Pimm Fox"
GlobeNewswire - Mon Mar 17, 3:43PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, is pleased to announce that Cheryl Pegus, M.D., President of Caluent, Director and Strategic Advisor of Glytec, and the Lead Independent Director of Vision-Sciences, will appear on a segment of the Bloomberg News TV show "Taking Stock with Pimm Fox" on Wednesday, March 19, 2014 during the 5:00 - 6:00 PM EDT hour.
Vision-Sciences to Present at BTIG's Inaugural Snowbird Medical Technology and Diagnostics Conference
GlobeNewswire - Thu Mar 13, 12:40PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, announced today that Howard Zauberman, President and Chief Executive Officer, will participate in BTIG's Inaugural Snowbird Medical Technology and Diagnostics Conference on Tuesday, March 18, 2014.
Patient Safety Awareness Week Brings Awareness to Health Care-Acquired Infection
GlobeNewswire - Tue Mar 04, 7:00AM CST
Vision-Sciences' EndoSheath Technology Provides Guaranteed Sterility
Hospitals Face New Superbug Liabilities
GlobeNewswire - Mon Feb 10, 7:02AM CST
Superbugs. Nightmare Bacteria. Antibiotic Resistant Strains. No matter what you call it, it's bad news for hospitals, which face increasingly stringent financial penalties under the Affordable Care Act. Specifically, patient readmissions and follow-up diagnostics due to hospital-acquired infections are increasingly not covered for reimbursement depending on the hospital's track record and other associated factors.
Vision-Sciences Announces Revenue of $4.5 Million for Third Quarter and $12.1 Million for First Nine Months of Fiscal 2014
GlobeNewswire - Mon Feb 03, 3:30PM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced financial results for the third quarter and first nine months of fiscal year 2014, ended December 31, 2013.
4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 31, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
Vision-Sciences to Host Third Quarter Fiscal 2014 Results Call
GlobeNewswire - Fri Jan 24, 8:44AM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the third quarter of fiscal 2014, ended December 31, 2013, after the market closes on Monday, February 3, 2014. Howard Zauberman, President and Chief Executive Officer, and Keith Darragh, VP, Finance, will host a conference call to discuss the results as follows:
4 Stocks Under $10 Moving Higher
at The Street - Wed Jan 15, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Vision-Sciences' EndoSheath(R) Technology Offers Patented Solution to "Nightmare Bacteria"
GlobeNewswire - Mon Jan 13, 7:00AM CST
An outbreak of "Nightmare Bacteria," also known as the "Super Bug," has raised new alarm bells in the healthcare industry over patient safety. The concern stems from 44 newly reported cases of cross-contamination infections as a result of endoscopic procedures done at Advocate Lutheran General Hospital, located just outside of Chicago.*
Vision-Sciences Selected as Preferred Vendor for Endoscopy Equipment by 21st Century Oncology
GlobeNewswire - Thu Dec 19, 7:00AM CST
Orangeburg, NY - December 19, 2013- Vision-Sciences, Inc. (NASDAQ: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, has entered into an agreement with 21 Century Oncology, Inc., under which Vision-Sciences is 21 Century's Preferred Vendor of Choice for endoscopy equipment used for evaluation and treatment procedures in multiple therapeutic and cancer care areas. The equipment agreement includes several of the company's advanced fiberoptic and video based endoscopic imaging products, including flexible laryngoscopes, transnasal esophagoscopes, bronchoscopes, and cystoscopes, all of which are utilized in the diagnosing, treatment, and management of head and neck, esophageal, lung, and bladder cancers.
Vision-Sciences Launches Authorized Repair Center for Europe
GlobeNewswire - Fri Dec 06, 7:00AM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced the full launch of the Company's official and authorized fiber and video endoscope repair center for Europe through an exclusive agreement with Rescope, a Netherlands-based facility dedicated to the technical management and repair of endoscopes.
Vision-Sciences Promotes Howard Zauberman to Chief Executive Officer and President, and Appoints Him to Board of Directors
GlobeNewswire - Tue Nov 26, 7:00AM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that effective today, Howard Zauberman, currently serving as Interim Chief Executive Officer, has been promoted to Chief Executive Officer and President. The Board also elected Mr. Zauberman to the Board of Directors to serve as a Class I director.
Annual ECRI List of Top 10 Health Technology Hazards Underscores Critical Need for Vision-Sciences' EndoSheath(R) Technology
GlobeNewswire - Mon Nov 18, 7:00AM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, announced today that for the fourth consecutive year, the ECRI Institute listed "Inadequate Reprocessing of Endoscopes and Surgical Instruments" among the top ten most dangerous technology hazards.
Vision-Sciences to Host One-on-Ones at Brean Capital 2013 Life Sciences Summit in NYC on November 25th
GlobeNewswire - Fri Nov 15, 12:00PM CST
Vision-Sciences, Inc. (Nasdaq:VSCI) announced today that Howard Zauberman, Interim Chief Executive Officer and Keith Darragh, VP Finance, will host one-on-one meetings at the Brean Capital 2013 Life Sciences Summit on November 25, 2013.
Vision-Sciences Announces Revenue of $4.0 Million for Second Quarter and $7.6 Million for First Half of Fiscal 2014
GlobeNewswire - Mon Nov 11, 3:30PM CST
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced financial results for its second quarter and first half of fiscal year 2014, ended September 30, 2013.
Evaluation at UK Deployed Field Hospital Demonstrates Advantages of Vision-Sciences' EndoSheath(R) Technology for Bronchoscopy
GlobeNewswire - Mon Sep 09, 7:40AM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, today announced positive results from a three-month evaluation completed in 2012 by the British Army at Camp Bastion, a deployed field hospital in Afghanistan. The research evaluated the efficacy and utility of our flexible bronchoscope with EndoSheath technology and its rapid, simplified cleaning routine versus conventional bronchoscopes, which require specialized, complicated disinfection processes between each use.
Vision-Sciences Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon Aug 12, 3:30PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI) today announced financial results for the first quarter of fiscal 2014, ended June 30, 2013. Highlights include:
Vision-Sciences to Discuss First Quarter of Fiscal 2014 Results on August 13 Conference Call
GlobeNewswire - Thu Aug 01, 3:30PM CDT
Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath(R) technology, today announced that the Company will release its financial results for the first quarter of fiscal 2014, ended June 30, 2013, after the market closes on Monday, August 12, 2013. Howard Zauberman, Interim Chief Executive Officer, and John Vittoria, Interim VP Finance, will host a conference call to discuss the results as follows:
